News

• PCR speekseltesten op de werkvloer identificeren besmette laag-risico contacten zonder symptomen en helpen de verdere verspreiding tegengaan

• Biogazelle lanceert speekseltest voor het opsporen van het COVID-19 virus op de werkvloer

• Biogazelle offering services to support COVID-19 vaccine & therapeutics development

• Biogazelle initiates large-scale testing for COVID-19 in Belgium

• Business continuity during the COVID-19 pandemic

• Biogazelle launches novel high-throughput RNA sequencing and data analysis services

• Biogazelle receives €499k Horizon 2020 funding to develop qPCR biomarker panels for multimorbidity associated with preterm birth

• Biogazelle CSO, Prof. Jo Vandesompele to present at ESHG 2019, Gothenburg

• From the archives: the idea behind the Biogazelle logo

• BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

• Biogazelle offers unique mRNA sequencing on plasma

• Biogazelle offers mRNA sequencing on plasma – interview with CSO prof. Jo Vandesompele

• Nature publishes study on melanoma addiction to the long non-coding RNA SAMMSON, providing solid proof-of-concept for Biogazelle’s lncRNA targeting anti-cancer platform

• Exiqon’s antisense products are best in class in new comparative study

• RXi Pharmaceuticals demonstrates potent reduction of long non-coding RNAs in collaboration with Biogazelle

• Biogazelle and Ionis Pharmaceuticals evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

• Biogazelle receives €1.1M IWT funding to develop lncRNA targeting cancer therapies

• Biogazelle offers unique microRNA sequencing on challenging samples

• Biogazelle strengthens its board of directors

• Biogazelle has established a quality management system and is ISO 17025 accredited for gene expression services

• UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth

• Biogazelle serves as reference laboratory for Bio-Rad's droplet digital PCR system

• Belgian company Biogazelle develops lab products beyond industry standards

• Biogazelle presents a revolutionary qPCR based lncRNA profiling platform